Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.12, expectations were $-1.58. Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc. (INO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 541,666.66,666,667 | $6,113,986 | 0% | ||
| 2. | D E Shaw D. E. Shaw | 225,096.83,333,333 | $1,377,593 | -52% | 0% |
| 3. | Millennium Management Israel Englander | 35,093.166,666,667 | $214,770 | -91% | 0% |
| 4. | 31,150 | $190,638 | +13% | 0% | |
| 5. | Tudor Investment Corp Paul Tudor Jones | 11,235 | $68,758 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.11 | 22,500 | Officer, Director | 1,100,707 | 2020-01-13 | Filing | |
| $2.22 | 4,500 | Officer | 50,333 | 2019-08-30 | Filing | |
| $2.50 | 20,000 | Officer | 45,833 | 2019-06-05 | Filing | |
| $6.25 | 21,300 | Director | 50,000 | 2017-03-27 | Filing | |
| $9.13 | 10,000 | Director | 142,291 | 2016-06-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.56 | 5,700 | Director | 52,716 | 2023-06-05 | Filing | |
| $1.15 | 5,833 | Director | 910,124 | 2023-03-13 | Filing | |
| $1.28 | 11,668 | Director | 904,291 | 2023-02-27 | Filing | |
| $2.66 | 11,875 | Director | 892,625 | 2022-08-11 | Filing | |
| $2.25 | 2,000 | Director | 75,305 | 2022-07-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,647,171.8,333,333 | $10,080,691 | 0% | |
| 2. | 474,166.66,666,667 | $5,329,196 | 0.04% | |
| 3. | Cnh Partners LlcBOND | 352,083.33,333,333 | $3,910,660 | 0.15% |
| 4. | 327,713.66,666,667 | $2,005,608 | 0% | |
| 5. | 239,287.08,333,333 | $1,464,759 | 0% |
News See All
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Inovio Third Quarter 2023 Financial Results Conference Call. At this time all lines are in a listen-only mode.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2023 Earnings Call Transcript
Operator: Good day, and welcome to the Inovio Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2023 Earnings Call Transcript
Operator: Good day and welcome to the Inovio First Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode for the duration of the call.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. Please note, this event is being recorded.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q3 2022 Earnings Call Transcript
Operator: Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. Please note that this event is being recorded. I would now like to turn the conference over to Thomas Hong.
10 Small-Cap Stocks to Sell Now Before Recession Begins
In this article, we discuss 10 small-cap stocks to sell now before recession begins.
5 Best Stocks Under $10 According to Billionaire Daniel Och's OZ Management
In this article, we discuss the 5 best stocks under $10 according to billionaire Daniel Och's OZ Management.
10 Best Vaccine Stocks to Buy Now
The mass COVID-19 vaccination drive has sent the stocks of publicly traded firms developing the vaccine into overdrive.
Inovio's (INO) INO-4800 can be a Valuable Vaccine Arsenal Upon FDA Approval
Wasatch Advisors, an employee-owned investment manager, published its ‘Wasatch Micro Cap Value Fund’ third-quarter 2020 Investor Letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
